Human applications of the INEL patient treatment planning system

Technical Report · Wed Nov 01 00:00:00 EST 1995

DOI:https://doi.org/10.2172/421331· OSTI ID:421331

Wheeler, F.; Wessol, D.; Atkinson, C.; Nigg, D. ^[1]

---

1. Idaho National Accelerator Lab., Idaho Falls, ID (United States)

During the past few years, murine and large animal research, as well as human studies have provided data to the point where human clinical trials have been initiated at the BMRR using BPA-F for gliomas and at the Massachusetts Institute of Technology Reactor (MITR) using BPA for melanomas of the extremeties. It is expected that glioma trials using BSH will proceed soon at the Petten High Flux Reactor (HFR) in the Netherlands. The first human glioma epithermal boron neutron capture therapy application was performed at the BMRR in the fall of 1994. This was a collaborative effort by BNL, Beth Israel Manhattan hospital, and INEL. The INEL planning system was chosen to perform dose predictions for this application.

• Research Organization: Lockheed Idaho Technologies Co., Idaho Falls, ID (United States)
• OSTI ID: 421331
• Report Number(s): INEL-95/0561; ON: DE96003995; TRN: 97:002185
• Resource Relation: Other Information: PBD: Nov 1995; Related Information: Is Part Of INEL BNCT Research Program annual report 1994; Venhuizen, J.R. [ed.]; PB: 83 p.
• Country of Publication: United States
• Language: English

Related Subjects

55 BIOLOGY AND MEDICINE
BASIC STUDIES
99 MATHEMATICS
COMPUTERS
INFORMATION SCIENCE
MANAGEMENT
LAW
MISCELLANEOUS
NEUTRON CAPTURE THERAPY
PLANNING
B CODES
ANIMALS
MAN
PROGRESS REPORT
EPITHERMAL NEUTRONS
BORON COMPOUNDS
BNL
GLIOMAS
MELANOMAS
RADIATION DOSES
PATIENTS
SODIUM COMPOUNDS
RADIATION TRANSPORT
FRACTIONATED IRRADIATION